Drugs during pregnancy and lactation: treatment options and risk assessment
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Buch |
| Sprache: | English German |
| Veröffentlicht: |
Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo
Elsevier
2015
|
| Ausgabe: | Third edition |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis Inhaltsverzeichnis |
| Beschreibung: | xxiv, 892 Seiten 24 cm |
| ISBN: | 9780124080782 0124080782 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV043721442 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 160817s2015 ne |||| 00||| eng d | ||
| 015 | |a 16,A17 |2 dnb | ||
| 016 | 7 | |a 1071573411 |2 DE-101 | |
| 020 | |a 9780124080782 |c Festeinband |9 978-0-12-408078-2 | ||
| 020 | |a 0124080782 |9 0-12-408078-2 | ||
| 035 | |a (DE-599)DNB1071573411 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 1 | |a eng |h ger | |
| 044 | |a ne |c XA-NL | ||
| 049 | |a DE-Er8 | ||
| 082 | 0 | |a 618.0461 |2 22/ger | |
| 084 | |a 610 |2 sdnb | ||
| 130 | 0 | |a Arzneimittel in Schwangerschaft und Stillzeit | |
| 245 | 1 | 0 | |a Drugs during pregnancy and lactation |b treatment options and risk assessment |c edited by Christof Schaefer, Paul Peters, and Richard K. Miller |
| 250 | |a Third edition | ||
| 264 | 1 | |a Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo |b Elsevier |c 2015 | |
| 300 | |a xxiv, 892 Seiten |c 24 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 0 | 7 | |a Arzneimittel |0 (DE-588)4003115-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Stillperiode |0 (DE-588)4183337-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Stillen |0 (DE-588)4057578-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Schwangerschaft |0 (DE-588)4053724-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 653 | |a Pregnancy--drug effects. | ||
| 653 | |a Drug Therapy--contraindications. | ||
| 653 | |a Drug-Related Side Effects and Adverse Reactions. | ||
| 653 | |a Fetus--drug effects. | ||
| 653 | |a Infant, Newborn. | ||
| 653 | |a Lactation--drug effects. | ||
| 653 | |a Pregnant women--Drug use. | ||
| 653 | |a Pregnant women--Medical care. | ||
| 653 | |a Obstetrical pharmacology--Handbooks, manuals, etc. | ||
| 653 | |a Fetus--Effect of drugs on--Handbooks, manuals, etc. | ||
| 653 | |a Newborn infants--Effect of drugs on--Handbooks, manuals, etc. | ||
| 653 | |a Fetus--Effect of drugs on. | ||
| 653 | |a Newborn infants--Effect of drugs on. | ||
| 653 | |a Obstetrical pharmacology. | ||
| 653 | |a Pregnant women--Drug use. | ||
| 653 | |a Pregnant women--Medical care. | ||
| 653 | |a Handbooks, manuals, etc. | ||
| 689 | 0 | 0 | |a Schwangerschaft |0 (DE-588)4053724-9 |D s |
| 689 | 0 | 1 | |a Stillen |0 (DE-588)4057578-0 |D s |
| 689 | 0 | 2 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 0 | 3 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Schwangerschaft |0 (DE-588)4053724-9 |D s |
| 689 | 1 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 1 | |8 1\p |5 DE-604 | |
| 689 | 2 | 0 | |a Stillperiode |0 (DE-588)4183337-5 |D s |
| 689 | 2 | 1 | |a Arzneimittel |0 (DE-588)4003115-9 |D s |
| 689 | 2 | |8 2\p |5 DE-604 | |
| 700 | 1 | |a Schaefer, Christof |d 1951- |0 (DE-588)132428474 |4 edt | |
| 700 | 1 | |a Peters, P. W. J. (Paul W. J.), |e Sonstige |4 oth | |
| 700 | 1 | |a Miller, Richard Kermit |d 1946- |e Sonstige |0 (DE-588)132890755 |4 oth | |
| 856 | 4 | 2 | |m B:DE-101 |q application/pdf |u http://d-nb.info/1071573411/04 |3 Inhaltsverzeichnis |
| 856 | 4 | 2 | |m DNB Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029133506&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029133506 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 883 | 1 | |8 2\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
Datensatz im Suchindex
| _version_ | 1804176513893924864 |
|---|---|
| adam_text | CONTENTS
LIST OF CONTRIBUTORS
PREFACE
DISCLAIMER
*
GENERAL COMMENTARY ON DRUG THERAPY AND DRUG RISKS *N PREGNANCY
PAUL PETERS. RICHARD K. MIUER AND CHRISTOS SCHAEFER
1.1 INTRODUCTION
1.2 DEVELOPMENT AND HEALTH
1.3 REPRODUCTIVE STAGES
1.4 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY
* .5 BASIC PRINCIPLES OF DRUG-INDUCED REPRODUCTIVE AND DEVELOPMENTAL
TOXICOLOGY
1.6 EFFECTS AND MANIFESTATIONS
1.7 PHARMACOKINETICS OF DRUGS IN PREGNANCY
1.8 MECHANISMS OF DEVELOPMENTAL TOXIC AGENTS
* .9 CAUSES OF DEVELOPMENTAL DISORDERS
1.10 EMBRYO/FETOTOXIC RISK ASSESSMENT AND PLAUSIBILITY
1.11 CLASSIFICATION OF DRUGS USED IN PREGNANCY
1.12 PATERNAL USE OF MEDICINAL PRODUCTS
1.13 COMMUNICATING THE RISK OF DRUG USE IN PREGNANCY
1.14 RISK COMMUNICATION PRIOR TO PHARMACOTHERAPEUTIC CHOICE
1 *15 RISK COMMUNICATION REGARDING THE SAFETY OF DRUGS ALREADY USED N
PREGNANCY
1.16 TERATOLOGY INFORMATION CENTERS
B S P E D F K D M G T H E
*
AP*ESD *
**
NG PREGNANCY
2.1 ANALGESICS, NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS).
MUSCLE RELAXANTS, AND ANTIGOUT MEDICATIONS
HELI MALM AND CORNELIA BORISCH
2.1.1 PARACETAMOL (ACETAMINOPHEN)
2.1.2 ACETYLSALICYLIC ACID
2.1.3 PYRAZOLONE COMPOUNDS AND PHENYLBUTAZONE
2.1.4 ANALGESIC DRUG COMBINATION PRODUCTS AND DRUGS USED FOR
OSTEOARTHRITIS
2.1.5 OPIOID AGONISTS AND ANTAGONISTS AND OTHER CENTRALLY ACTING
ANALGESICS
2.1.6 NON-STEROIDAL ANTIINFLAMMATORY AND ANTIRHEUMATIC DRUGS
2.1.7 MIGRAINE THERAPY
2.1.8 MUSCLE RELAXANTS AND OTHER ANALGESICS
2.1.9 ANTIGOUT PREPARATIONS
2.2 ALLERGY AND HYPOSENSITIZATION THERAPY
LEE H. GOLDSTEIN, CORINNA W EBERSCHONDORFER AND
M ATITIAHU BERKOVITCH
2.2.1 ANTIHISTAMINES (HSBLOCKER)
2.2.2 HYPOSENSITIZATION THERAPY
2.2.3 CL -ESTERASE INHIBITS DEFICIENCY
XIX
XXIII
XXV
1
2
3
4
8
10
11
13
14
15
17
18
19
20
21
21
27
29
32
33
34
41
46
48
49
59
61
61
2.3 ANTIASTHMATIC AND COUGH MEDICATION
LEE H. GOLDSTEIN, CORINNA W EBERSCHONDORFER
AND M A TITIA H U BERKOVITCH
2.3.1 SELECTIVE (
*
-ADRENERGIC AGONISTS 66
2.3.2 INHALED CORTICOSTEROIDS (ICSS) 67
2.3.3 THEOPHYLLINE 68
2.34 LEUKOTRIENE ANTAGONISTS 69
2.3.5 MAST CELL STABILIZERS (INHIBITORS) 69
23.6 ANTICHOLINERGICS 70
2.3.7 OMALIZUMAB AND ROFLUMILAST 70
2.3.8 EXPECTOANTS AND MUCOLYTIC AGENTS 70
2.3.9 ANTITUSSIVES 71
2.3.10 NON-SELECTIVE (VADRENERGIC AGONISTS 72
2.4. NAUSEA AND VOMITING IN PREGNANCY
LEE H. GOLDSTEIN, CORINNA W EBERSCHONDORFER
AND M A TITIA H U BERKOVITCH
2.4.1 TREATMENT OPTIONS 76
2.4.2 COMPLEMENTARY TREATMENT OPTIOS 76
2.4.3 PHARMACOLOGICAL TREATMENT OPTIONS 78
2.4.4 DOPAMINE ANTAGONISTS 81
2.4.5 PYRIDOXINE (VITAMIN *6) 83
2.4.6 VITAMIN BL 84
2.4.7 SEROTONIN ANTAGONISTS 85
2.4.8 GLUCOCORTICOIDS 86
2.4.9 OTHER ANTIEMETICS 86
2.5. GASTROINTESTINAL MEDICATIONS, HYPOLIPIDEMIC AGENTS AND SPASMOLYTICS
M AURIZIO CLEMERITI AND CORINNA W EBERSCHONDORFER
2.5.1 ANTACIDS 94
2.5.2 SUCRALFATE AND PIRENZEPINE 95
2.5.3 H2 RECEPTOR ANTAGONISTS 95
2.5.4 PROTON PUMP INHIBORS 96
2.5.5 BISMUTH SALTS 97
2.5.6 HELICOBACTER PYLORI THERAPY 97
2.5.7 DIGESTIVES AND CARMINATIVES 98
2.5.8 ATROPINE AND OTHER ANTICHON^ 98
2.5.9 CHOLINERGICS 99
2.5.10 CONSTIPATION DURING PREGNANCY 99
2.5.11 ANTIDJARRHEAL AGENTS 102
2.5.12 MEDICATIONS FOR INFLAMMATORY BOWEL DISEASE 103
2.5.13 CHENODESOXYCHOLIC ACID AND URSODEOXYCHOLIC ACID 104
2.5.14 LIPID LOWERING AGENTS 105
2.5.15 APPETITE SUPPRESSANTS, WEIGHT LOSS MEDICATIONS, AND OBESITY 108
2.6. ANTI-INFECTIVE AGENTS
STEPHANIE PADBERG
2.6.1 PENICILLINS AND [VLACTAMASE INHIBITORS 116
2.6.2 CEPHALOSPORINS 117
2.6.3 CARBAPENEMS AND MONOBACTAMS 117
2.6.4 ERYTHROMYCIN AND OTHER MACROLIDES 118
2.6.5 CLINDAMYCIN AND ****** 119
2.6.6
TETRACYCLINES
120
2.6.7 SULFONAMIDES AND TRIMETHOPRIM
121
2.6.8 QUINOLONES
122
2.6.9
NITROFURANS AND DRUGS FOR URINARY TRACT INFECTIONS 123
2.6.10 NITROIMIDAZOLE ANTIBIOTICS
125
2.6.11 AMINOGLYCOSIDES
125
2.6.12
GLYCOPEPTJDE AND POLYPEPTIDE ANTIBIOTICS
126
2.6.13
OTHER ANTIBIOTICS
127
2.6.14 TUBERCULOSIS AND PREGNANCY
129
2.6.15
LOCAL ANTIBIOTICS
132
2.6.16
MALARIA PROPHYLAXIS AND TREATMENT IN PREGNANCY
132
2.6.17 AZOLE ANTIFUNGALS
139
2.6.18
AMPHOTERICIN B
141
2.6.19
ECH*NOCANDJNS
141
2.6.20
FLUCYTOSINE
**
2.6.21 GRISEOFULVIN
142
2.6.22 TERBINAFINE
143
2.6.23
TOPICAL ANTIFUNGAL AGENTS
143
2.6.24 ANTHELMINTICS
144
2.6.25
HERPES MEDICATIONS
147
2.6.26
ANTIVIRAL DRUGS FOR HEPATITIS
148
2.6.27 ANTIVIRAL DRUGS FOR INFLUENZA
150
2.6.28
ANTIRETROVIRAL AGENTS
151
2.6.29
OVERVIEW OF THE ANTIRETROVIRAL MEDICATIONS
152
2.6.30
2.6.31
NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE
INHIBITORS (NRTLS)
NON-NUCLEOSLDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIS)
153
155
2.6.32
PROTEASE INHIBITORS (PIS)
157
2.6.33
ENTRY INHIBITORS
160
2.6.34 INTEGRASE INHIBITORS
161
2.6.35
HYPERTHERMIA
162
2.6.36
LOG-DISTANCE TRAVEL AND FLIGHTS
162
VACCINES AND IMMUNOGLOBULINS
BENEDIKTE-NOEL CUPPERS AND CHRISTOS SCHAEFER
2.7.1 THIOMERSAL AS A PRESERVATIVE FOR VACCINES
178
2.7.2
CHOLERA VACCINATION
179
2.7.3
DIPHTHERIA AND TETANUS VACCINATION
179
2.7.4
HAEMOPHILUS INFLUENZA B (HIB) VACCINATION
180
2.7.5
HEPATITIS A AND HEPATITIS B VACCINATION
180
2.7.6
HPV VACCINATION
180
2.7.7
INFLUENZA VACCINATION
181
2.7.8
MEASLES AND MUMPS VACCINATION
183
2.7.9
MENINGOCOCCAL VACCINATION
183
2.7.10
PERTUSSIS VACCINATI^
184
2.7.11
PNEUMOCOCCAL VACCINATION
184
2.7.12
POLIOMYELITIS VACCINATION
184
2.7.13
RABIES VACCINATION
185
2.7.14
RUBELLA VACCINATO!
185
2.7.15
TICK-BORNE ENCEPHALITIS VACCINATION
186
2.7.16
TYPHOID VACCINATION
186
2.7.17
VARICELLA VACCINATION
187
2.7.18
YELLOW FEVER VACCINATION
187
2.7.19
IMMUNOGLOBULINS
188
2.8. HEART AND BLOOD MEDICATIONS
FERNANDA SALES LUIZ VIANNA. LAVINIA SCHULER-FACCINI AND CORINNA
W EBERSCHONDORFER
2.8.1 ARTERIAL HYPERTENSION AND P R G 194
2.8.2 (X-METHYLDOPA 195
2.8.3 ()-RECEPTOR BLOCKERS 196
2.8.4 CALCIUM CHANNEL BLOCKERS 198
2.8.5 ACE INHIBITORS 199
2.8.6 ANGIOTENSIN
**
RECEPTO BLOCKERS (ARBS; SARTANS) 200
2.8.7 DIHYDRALAZINE 202
2.8.8 BLOCKERS (PERIPHERAL
*
ACTING ADRENERGIC ANTAGON^^ 202
2.8.9 (*-2 BLOCKERS CENTRALLY ACTING ADRENERGIC ANTAGONISTS) 203
2.8.10 OTHER ANTIHYPERTENSIVE MEDICATIONS 204
2.8.11 PULMONARY HYPERTENSION AND PREGNANCY 205
2.8.12 HYPOTENSION AND ANTLHYPOTENSIVE DRUGS 207
2.8.13 ADRENERGIC AGENTS 208
2.8.14 CARDIAC GLYCOSIDES 208
2.8.15 ANTIARRHYTHMIC MEDICATIONS 208
2.8.16 COONARY THERAPEUTID 213
2.8.1
* VASOCIRCULATORY DRUGS AND PERIPHERAL VASODILATORS 214
2.8.18 DIURETICS 215
2.9. ANTICOAGULANTS, THROMBOCYTE AGGREGATION INHIBITORS, FIBRINOLYTICS
AND VOLUME REPLACEMENT AGENTS
JANINE E. POLIFKA AND JULIANE HABERMANN
2.9.1 INDICATIONS FOR ANTICOAGULATION 226
2.9.2 HEPARINS AND DANAPAROID 227
2.9.3 PROTAMINES 229
2.9.4 THROMBIN-INHIBITORS 230
2.9.5 FACTOR XA INHIBITORS 231
2.9.6 INHIBITORS OF THROMBOCYTE AGGE^ 231
2.9.7 VITAMIN K ANTAGONISTS 233
2.9.8 VITAMIN K 237
2.9.9 FIBRINOLYSIS 238
2.9.10 STREPTOKINASE 239
2.9.11 ANTIHEMORRHAGICS 239
2.9.12 OTHER ANTIHEM^RHAGICS 240
2.9.13 VOLUME REPLACEMENT SUBSTANCES AND RHEOLOGIES 241
2.10. EPILEPSY AND ANTIEPILEPTIC MEDICATIONS
CHRISTINA CHAMBERS AND CHRISTOS SCHAEFER
2.10.1 ANTIEPILEPTIC THERAPY 252
2.10.2 ANTIEPILEPTIC AND CONTRACEPTIVE DRUGS 253
2.10.3 EPILEPSY AND FERTILITY 253
2.10.4 FREQUENCY OF SEIZURES IN PREGNANCY 254
2.10.5 RISK OF MALFORMATIONS 254
2.10.6 TYPICAL MALFORMATIONS AND OTHER ANOMALIES 256
2.10.7 PREGNANCY COMPLICATIONS 256
2.10.8 MENTAL DEVELOPMENT DYSFUNCTION 257
2.10.9 ..DAMAGE MECHANISMS 258
2.10.10 FOLIC ACID AND ANTIEPILEPTIC DRUGS 259
2.10.11 VITAMIN K AND ANTIEPILEPTIC DRUGS 259
2.10.12
IS EPILEPSY TERATOGENIC? 260
2.10.13 CARBAMAZEPINE 260
2.10.14
CLOBAZAM AND CLONAZEPAM
263
2.10.15
ESLICARBAZEPINE 264
2.10.
*
6 ETHOSUXIMIDE AND OTHER SUCCINIMIDES 264
2.10.17
FELBAMATE
265
2.10.18
GABAPENTIN
265
2.10.19
LACOSAMIDE
266
2_10_20
LAMOTRIGINE
267
2.10.21 LEVETIRACETAM 268
2.10.22
OXCARBAZEPINE 269
2.10.23
PHENOBARBITAL AND PRIMIDONE 270
2.10,24
PHENYTOIN
273
2.10.25
PREGABALIN
274
2.10.26 RUFINAMIDE
275
2.10.27 SULTIAME
275
2.10.28
TIAGABINE
275
2.10.29 TOPIRAMATE
276
2.10.30
VALNOCTAMIDE
*
* *
2.1031
VALPROIC ACID
278
2.10.32 VIGABATRIN
282
2.10.33 ZONISAMIDE
283
2.11* PSYCHOTROPIC DRUGS
KATHERINE
*
WISNER AND CHRISTOS SCHAEFER
2.11.1
PSYCHIATRIC DISORDER DURING PREGNANCY
294
2.11.2 ANTIDEPRESSANT TREATMENT
294
2.11.3
SELECTIVE SEROTONIN-REUPTAKE-INHIBITORS (SSRI)
295
7114
TRI- AND TETRACYCLIC ANTIDEPRESSANTS
302
2.11.5
INDIVIDUAL ANTIDEPRESSANTS
303
2.11.6
ANTIPSYCHOTIC TREATMENT
313
2.11.7 INDIVIDUAL ANTIPSYCHOTIC DRUGS
316
2.11.8
LITHIUM AND OTHER ANTI-MANIC AGENTS
322
2.11.9
ANXIOLYTICS, HYPNOTICS, SEDATIVES N GENERAL
324
2.1110
BENZODIAZEPINES
325
2.11.11
ZALEPLON. ZOLPIDEM AND ZOPICLONE
327
2.11.12
OTHER ANXIOLYTICS AND HYPNOTICS
328
2.1113
PSYCHOANALEPTICS
328
2.11 *14 ANTI-PARKINSON DRUGS AND RESTLESS LEGS SYNDROME
2.12. IMMUNOSUPPRESSION, RHEUMATIC DISEASES, MULTIPLE SCLEROSIS,
AND WILSON S DISEASE
CORMNA WEBER-SCHONDORFER
329
2.12.1
AZATHI0PRINE/6-ME
*
CAP^^^
341
2.12.2
SELECTIVE IMMUNOSUPPRESSANTS
342
2.12.3 BIOLOGIC
345
7174
MULTIPLE SCLEROSIS
352
2.12.5
INTERFERONS
354
2.12.6
OTHER IMMUNOSTIMULATORY DRUGS
356
2.12.7 TRANSPLANTATION
358
2.12.8 DRUGS FOR RHEUMATIC DISEASES
358
2.12.9 DRUGS FOR WILSON S DISEASE
363
2.13. ANTINEOPLASTIC DRUGS
JAN M. FRIEDMAN AND CORINNA W EBERSCHONDORFER
2.13.1 MALIGNANCY AND PREGNANCY
2.13.2 BREAST CANCER
2.13.3 VINCA ALKALOIDS AND ANALOGS
2.13.4 PODOPHYLLOTOXIN DERIVATIVES
2.13.5 NITROSOUREA ALKYLATORS
2.13.6 NITROGEN MUSTARD ANALOG ALKYLATORS
2.13.7 OTHER ALKYLATING AGENTS
2.13.8 CYTOTOXIC ANTHRACYCLINE ANTIBIOTICS
2.13.9 OTHER CYTOTOXIC ANTIBIOTICS
2.13.10 OLATE ANTAGONISTS
2.13.11 PURINE ANTAGONISTS
2.13.12 PYRIMIDINE ANTAGONISTS
2.13.13 TAXANES AND OTHER CYTOSTATIC AGENTS
2.13.14 MONOCLONAL ANTIBODIES
2.13.15 PLATIN COMPOUNDS
2.13.16 THALIDOMIDE AND ITS ANALOGS
2.13.17 TYROSINE KINASE INHIBITORS
2.13.18 ANTINEOPLASTIC DRUGS WITH ENDOCRINE EFFECTS
2.13.19 OTHER ANTINEOPLASTIC AGENTS
2.14. UTERINE CONTRACTION AGENTS, TOCOLYTICS, VAGINAL THERAPEUTICS
AND LOCAL CONTRACEPTIVES
GERARD H. A. VISSER AND ANGELA KAYSER
2.14.1 PROSTAGLANDINS
2.14.2 OXYTOCIN
2.14.3 ERGOT ALKALOIDS
2.14.4 TOCOLYTICS IN GENERAL
2.14.5 SS2-SYMPATHOMIMETICS
2.14.6 CALCIUM ANTAGONISTS
2.14.7 MAGNESIUM SULFATE
2-14.8 OXYTOCIN RECEPTO ANTAGONISTS
2.14.9 PROSTAGLANDIN ANTAGONISTS
2.14.10 OTHER TOCOLYTICS
2.14.11 VAGINAL THERAPEUTICS
2.14.12 SPERMICIDE CONTRACEPTIVES
2.14.13 INTRAUTERINE DEVICE
2.15* HORMONES
ASHER ORNOY AND CORINNA W EBERSCHONDORFER
2.15.1 HYPOTHALAMIC RELEASING HORMONES
2.15.2 ANTERIOR PITUITARY HORMONES
2.15.3 PROLACTIN ANTAGONISTS/DOPAMINE AGONISTS
2.15.4 POSTERIOR PITUITARY HORMONES
215.5 THYROID FUNCTION AND *ODINE SUPPLY DURING PREGNANCY
2.15.6 HYPOTHYROIDISM, TRIIODOTHYRONINE (**) AND THYROXIN (*4)
2.15.7 HYPERTHYROIDISM AND THYROSTATICS
2.15.8 GLUCOCORTICOIDS
2.15.9 DIABETES MELLITUS AND PREGNANCY
2.15.10 INSULIN
2.15.11 ORAL ANTIDIABETICS (OAD)
4
6
7
7
8
8
9
.
1
2
3
3
5
5
6
7
8
9
.
7
7
7
7
7
7
7
*
*
*
*
*
*
*
*
8
8
5
*
8
8
*
*
0
*
9
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
1
3
4
5
6
7
7
0
*
*
*
9
9
0
0
.
0
0
0
0
0
0
0
0
0
0
1
1
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
3
6
8
.
2
2
2
3
2.15.12 ESTROGENS 434
2.15.13 GESTAGENS 435
2.15.14 DUOGYNON 437
2.15.15 DIETHYLSTILBESTROL 437
2.15.16 ANDROGENS AND ANABOLICS 438
2.15.17 CYPROTERONE AND DANAZOL 439
2.15.18 MIFEP
*
STONE(RU486) 440
2.15.19 CLOMIPHENE 440
2.15.20 ERYTHROPOIETIN 441
2.16. GENERAL AND LOCAL ANESTHETICS AND MUSCLE RELAXANTS
STEFANIE HULTZSCH AND ASHER ORNOY
2.16.1 HALOGENATED INHALATIONAL ANESTHETIC AGENTS 452
2.16.2 ETHER (DIETHYJ ETHER) 454
2.16.3 NITROUS OXIDE 454
2.16.4 XENON 454
2.16.5 OCCUPATIONAL EXPOSURE TO ANESTHETIC GASES 454
2.16.6 INJECTION ANESTHETICS 455
216.7 LOCAL ANESTHETICS 457
2.16.8 MUELE RELAXANTS 460
2.17. DERMATOLOGICAL MEDICATIONS AND LOCAL THERAPEUTICS
GUDULA KIRTSCHIG AND CHRISTOS SCHAEFER
2.17.1 TYPICAL SKIN CHANGES DURING PREGNANCY 468
2.17.2 ANTISEPTICS AND DISINFECTANTS 468
2.17.3 GLUCOCORTICOIDS AND ***-STEROID ANTIPHLOGISTICS 471
2.17.4 ASTRINGENTS 471
2.17.5 ANTIPRURITICS AND ESSENTIAL OILS 472
2.17.6 COAL TAR AND SLATE OIL PREPARATIONS M
2.17.7 LOCAL IMMUNOMODULATORS AS THERAPY FOR ATOPIC ECZEMA 473
2.17.8 KERATOLYTICS 473
2.17.9 RETINOIDS FOR ACNE AND PSORIASIS THERAPY 475
2.17.10 ULTRAVIOLET LIGHT 479
2.17.11 FUMARIE ADD PREPARATIONS 479
2.17.12 BIOLOGICALS 480
2.17.13 WART THERAPEUTICS 480
2.17.14 LITHIUM 481
2.17.15 LICE MEDICATIONS 481
2.17.16 ANTI-SCABIES 482
2.17.17 VEIN THERAPEUTICS 483
2.17.18 ANTH*D
**
TCA 483
2.17.19 EFLORNITHINE. FINASTERIDE AND MINOXIDIL 484
2.17.20 REPELLENTS 485
2.17.21 COSMETICS 485
2.17.22 EYE, NOSE AND EAR DROPS 486
2.17.23 HEMORRHOID MEDICATION 488
2.17.24 VAGINAL THERAPEUTICS 488
2.18. VITAMINS, MINERALS AND TRACE DEMENTS
RICHARD K. M I**E* AND PAUL PETERS
2.18.1 VITAMIN A (RETINOL) 494
2.18.2 VITAMIN B
*
(THIAMINE) 496
2.18.3 VITAMIN *2 (RIBOFLAVIN)
2.18.4 VITAMIN *3 (NICOTINAMIDE)
2.18.5 VITAMIN *6 (PYRIDOXINE)
2.18.6 VITAMIN **
2
(CYANOCOBALAMIN)
2.18.7 VITAMIN C (ASORBIC ACID)
2.18.8 FOLIC ACID
2.18.9 VITAMIN D GROP
2.18.10 VITAMIN E (TOCOPHEROL)
2.18.11 VITAMIN K
2.18.12 MULTIVITAMIN PREPARATIES
2.18.13 IRON
2.18.14 CALCIUM
2.18.15 FLORIDE
2.18.16 STRONTIUM
2.18.17 BIPHOSPHONATES AND OTHER OSTEOPOROSIS DRUGS
2.18.18 IODIDE
2.18.19 TRACE ELEMENTS
2.19. HERBS DU *
*NG PREGNANCY
HENRY M. HESS AND RICHARD K. M ILLE R
2.19.1 THE SAFETY OF HERBS DURING PREGNANCY
2.19.2 COUNSELING A PREGNANT WOMAN A BUT HERBS
2.19.3 GENERAL CONCEPTS REGARDING THE USE OF HERBS DURING PREGNANCY
2.19.4 HERBS USED AS FOODS
2.19.5 ESSENTIAL OILS THAT ARE SAIE DURING PREGNANCY
2.19-6 HERBS FREQUENTLY USED DURING PREGNANCY
2.19.7 HERBS CONTROVERSIALLY USED DURING PREGNANCY
2.19.8 HERBS CONTRAINDICATED DURING PREGNANCY
2.20. DIAGNOSTIC AGENTS
STEFANIE HULTZSCH
2.20.1 DIGNOSTIC IMAGING
2.20.2 CONTRASTMEDIA
2.20.3 RADIOACTIVE ISOTOPES
2.20.4 STABLE ISOTOPES
2.20.5 DYES
2.20.6 OTHER DIAGNOSTIC AGENTS
2.21 RECREATIONAL DRUGS
SALLY STEPHENS AND LAURA M. YATES
INTRODUCTION
2.21.1 ALCOHOL
2.21.2 CAFFEINE AND OTHER XANTHINES
2.21.3 TOBACCO AND SMOKING
2.21 *4 DRUGS OF ABUSE *N GENERAL (EXCLUDING CAFFEINE)
2.21.5 SEDATING DRUGS
2.22. POISONINGS AND TOXINS
LAURA M. YATES AND SALLY STEPHENS
2.22.1 THE GENERAL RISK OF POISONING IN PREGNANCY
2.22.2 TREATMENT OF POISONING IN PREGNANCY
2.22.3 MEDICINES
6
7
7
7
8
0
0
1
2
3
3
3
4
5
6
6
7
7
9
9
0
*
9
9
9
0
0
0
0
0
0
0
0
0
0
0
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
*
*
*
*
*
*
2.23. OCCUPATIONAL, INDUSTRIAL AND ENVIRONMENTAL AGENTS
SUSAN M. BARLOW, FRANK * *. SU** VAN AND RICHARD K. MIUER
2.23.1 SO/ENT EXPOSURE IN GENERAL
2.23.2 FORMALDEHYDE AND FORMALIN
2.23.3 PHOTOGRAPHIC/PRINTING
2.23.4 PESTICIDES
2.23.5 PHENOXYACETIC ADD DERIVATIVES AND POLYCHLORINATED
DIBENZO-DIOXINS
2.23.6 POLYCHLORINATED BIPHENYLS
2.23.7 CHLORINATED DRINKING W A
2.23.8 METALS
2.23.9 HAZARDOUS WASTE LANDFILL SITES AND WASTE INCINERATES
2.23.10 RADIATION ASSOCIATED WITH THE NUCLEAR INDUSTRY
2.23.11 CELL/MOBILE PHONES
2.23.12 OTHER SOURCES OF ELECTROMAGNETIC RADIATION
2.23.13 ELECTRIC SHOCKS AND LIGHTNING STRIKES
*
GENERAL COMMENTARY ON DRUG THERAPY AND DRUG RISK DURING LACTATION
RUTH A. LAWRENCE AND CHRISTOS SCHAEFER
3.1 THE ADVANTAGES OF BREASTFEEDING VERSUS THE RISKS OF MATERNAL
MEDICATION 639
3.2 THE PASSAGE OF MEDICATIONS INTO THE MOTHER S MILK 641
3.3 INFANT CHARACTERISTICS 642
3.4 MILK PLASMA RATIO 643
3.5 AMOUNT OF MEDICATION IN 644
3.6 TOXICITY OF MEDICATIONS N 645
3.7 MEDICATIONS THAT AFFECT LACTATION 647
3.8 BREASTFEEDING SUPPOT 648
*
SPECIFIC DRUG THERAPIES DURING LACTATION
4.1. ANALGESICS, ANTIPHLOGISTICS AND ANESTHETICS
MARIA EUFOLK AND STEFANIE HULTZSCH
4.1.1 PARACETAMOL
653
417
ACETYLSAHSYLICACID
654
4.1.3 PYRAZOLONE AND PHENYLBUTAZONE DERIVATIVES
655
4.1.4 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAID) 655
4.15 SELECTIVE COX-2 INHIBITORS
657
4.1.6 OTHER ANTIRHEUMATICS
658
4.17 MIGRAINE MEDICATIONS 659
4.1.8 OPIOIDS AND OPIOID DERIVATIVES 660
4.1.9 LOCAL ANESTHETICS 664
4.1.10
OTHER MEDICATIONS USED IN CONNECTION WITH ANESTHESIA 665
4.1.11 MYOTONOLYTICS AND OTHER ANALGESICS 666
4.1.12 GOUT THERAPY 666
2.22.4 ANIMAL TOXINS
590
2.22.5
MUSHROOMS
592
2.22.6 OTHER PLANT TOXINS
592
2.22.7 BACTERIAL ENDOTOXINS
592
1
7
7
*
0
0
0
0
0
6
6
6
6
2
4
4
6
2
3
5
5
7
1
1
1
1
2
2
2
2
2
6
6
6
6
V
B
6
6
V
#
O
6
4.2. ANTIALLERGICS, ANTIASTHMATICS AND ANTITUSSIVES
PAUL M ERLOB AND CORINNA W EBERSCHONDORFER
4.2.1 ANTIHISTAMINES (HSBLOCKER) 671
4.2.2 SELECTIVE EFFECTIVE P2 SYMPATHOMIMETICS 672
4.2.3 INHALABLEORTICOSTEROIDS(ICS) 673
4.2.4 LEUKOTRIEN-RECEPTOR ANTAGONISTS 673
4.2.5 THEOPHYLLINE 674
4.2.6 MAST CELL INHIBIOS 674
4.2.7 ANTICHOLINERGICS FOR ASTHMA TREATMENT 674
4.2.8 OMALIZUMAB 675
4.2.9 MUCOLYTICS, EXPECTORANTS AND COLD REMEDIES 675
4.2.10 ANTITUSSIVES 675
4.3. GASTROINTESTINAL DUGS
PAUL M ERLOB AND CORINNA W EBERSCHONDORFER
43.1 GASTRITIS AND ULCER MEDICATIONS 677
43.2 PERISTALTIC STIMULATES 679
4.3.3 CHOLINERGICS 680
4.3.4 ANTICHOLINERGIC SPASMOLYTICS 681
4.3.5 LAXATIVES 681
4.3.6 AGENTS USED FOR CHRONIC
*
1
*
682
4.3.7 ANT*D*A
**
HEALSF(5
*
ACUTE DIARRHEA 683
4.3.8 DIGESTIVES AND CARMINATIVES 683
43.9 LIPID REDUCERS 683
4.3.10 CHENODEOXYCHOLIC ACID AND URSODEOXYCHOLIC ACID 684
4.3.11 APPETITE SUPPRESSANTS 684
4.3.12 ANTIEMETICS 684
4 4
ANTI-INFECTIVES
STEPHANIE PADBERG
4.4.1 PENICILLINS, CEPHALOSPORINS AND OTHER P-LACTAM ANTIBIOTICS 688
4.4.2 ERYTHROMYCIN AND OTHER MACROD^ 688
4.4.3 TETRACYCLINES 689
4.4.4 SULFONAMIDES AND TRIMETHOPRIM 689
4.4.5 QUINOLONES 690
4.4.6 NITROFURANS AND DRUGS SO URINARY TRACT INFECTIONS 690
4.4.7 NITROIMIDAZOLE ANTIBIOTICS 691
4.4.8 AMINOGLYCOSIDES 692
4.4.9 GLYCOPEPTIDE AND POLYPEPTIDE ANTIBIOTICS 692
4.4.10 OTHER ANTIBIOTICS 692
4.4.11 TUBERCULOSTATICS 693
4.4.12 LOCAL ANTIBIOTICS 694
4.4.13 ANTIMALARIAL MEDICATION 695
4.4.14 SYSTEMIC ANTIFUNGAL AGENTS 696
4.4.15 TOPICAL ANTIFUNGAL AGENTS 696
4.4.16 ANTHELMINTICS 697
4.4.17 ANTIVIRAL AGENTS 697
4.5. VACCINES AND IMMUNOGLOBULINS
RUTH A. LAWRENCE AND MARY PANSE
4.5.1 MATERNAL IMMUNIZATION 705
4.5.2 EFFICACY OF IMMUNIZATION N BREASTFED INFANTS 706
4.5.3 HEPATITIS A VACCINE
4.5.4 HEPATITIS B VACCINE
4.5.5 HUMAN PAPILLOMAVIRUS VACCINE
4.5.6 INFLUENZA VACCINE
4.5.7 POLIOVACCINE
4.5.8 RABIESVACCINE
4.5.9 RUBELLA VACCINE
4.5.10 SMALLPOX ACCINE
4.5.11 TYPHOID VACCINE
4.5.12 IMMUNOGLOBULINS
4.5.13 CDC RECOMMENDATIONS
4.6. CARDIOVASCULAR DRUGS AND D
PAUL M ERLOB AND CORINNA W EBERSCHONDORFER
4.6.1 P-RECEPTOR BLOCKERS
4.6.2 HYDRALAZINE
4.6.3 -METHYLDOPA
4.6.4 CALCIUM ANTAGONISTS
4.6.5 ACE INHIBITORS
4.6.6 ANGIOTENSIN-LL RECEPTOR-ANTAGONISTS (SARTAN)
4.6.7 OTHER ANTIHYPERTENSIVES
4.6.8 ANTIHYPOTENSIVES
4.6.9 DIGITALIS
4.6.10 ANTIARRHYTHMICS
4.6.11 VASODILATORS AND CIRCULATORY DRUGS
4.6.12 DIURETICS
4.7. ANTICOAGULANTS, THROMBOCYTE AGGREGATION INHIBITORS AND
FIBRINOLYTICS
PAUL M ERLOB AND JULIANE HABERMANN
4.7.1 HEPARIN AND DANAPAROID
4.7.2 THROMBIN- AND FACTOR XA-INHIBITORS
4.7.3 THROMBOCYTE AGGREGATION INHIBITORS
4.7.4 VITAMIN K-ANTAGONISTS
4.7.5 FIBRINOLYTICS
47.6 ANTIHEMORRHAGICS
4.7.7 VOUME EXPANDERS
4.8 ANTIEPILEPTJCS
PAUL M ERLOB AND CHRISTOS SCHAEFER
4.8.1 INTRODUCTION
4.8.2 INDIVIDUAL ANTIEPILEPTICS
4.9. PSYCHOTROPIC DRUGS
PAUL M ERLOB AND CHRISTOS SCHAEFER
4.9.1 INTRODUCTION
4.9.2 ANTIDEPRESSANTS
4.9.3 INDIVIDUAL ANTIDEPRESSANTS
4.9.4 ANTIPSYCHOTIC
4.9.5 INDIVIDUAL ANTIPSYCHOTIC DRUGS
4.9.6 LITHIUM AND OTHER ANTIMANIC DRUGS
4.9.7 ANXIOLYTICS, HYPNOTICS AND SEDATIVES
4.9.8 BENZODIAZEPINES
6
6
7
7
7
*
*
*
*
8
*
*
9
9
*
*
*
*
*
*
*
*
*
*
*
3
4
5
5
6
**
**
17
.19
.20
2
2
2
2
2
2
2
7
7
7
7
7
7
7
73
73
74
*
74
*
74
*
75
*
75
*
76
*
76
*
76
*
4.9.9 ZALEPLON, ZOLPIDEM AND 767
4.9.10 OTHER ANXIOLYTICS, HYPNOTICS AND SEDATIVES 767
4.9** PSYCHOANALEPTICS 768
4.9.12 ANTI-PARKINSON DRUGS 769
4.10. IMMUNOMODULATING AND ANTINEOPLASTIC AGENTS
PAUL M ERLOB AND CORINNA W EBERSCHONDORFER
4.10.1 AZATHIOPRINE AND E.MERCAPTOPURINE 775
4.102 SELECTIVE IMMUNE SUPPRESSANT^ 776
4.103 MONOCLONAL ANTIBODIES (MAB) AND OTHER BIOLOGICALS 777
4.10.4 INTERFERONS 778
4.10.5 0THE
*
IMMUNE STIMULANTS 779
4.10.6 ANTINEOPLASTICS 779
4.11. HORMONES AND HORMONE ANTAGONISTS
GERARD *.*. VISSER AND CORINNA W EBERSCHONDORFER
4.11.1 PITUITARY AND HYPOTHALAMIC HORMONES 783
4.11.2 METHYLERGOMETRINE(METHYLE
*
GONOVINE) 784
4.11.3 BROMOCRIPTINE AND OTHER PROLAC^ 785
4.11.4 THYROID HORMONES AND THYROID RECEPTOR ANTIBODIES (TRAB) 785
4.11.5 THYROSTATICS 786
4.11.6 IODINE 787
4.11.7 CORTICOSTEROIDS 788
4.11.8 ADRENALINE 789
4.11.9 INSULIN AND ORAL ANTIDIABETICS 789
4.11 *10 ESTROGENS, GESTAGENS, AND HORMONAL CONTRACEPTIVES 790
4.11.11 ANDROGENS AND ANABOLICS 792
4.11 *12 CYPROTERONE ACETATE AND OTHER SEX.HORMONE INHIBITORS 792
4.11.13 PROSTAGLANDINS 793
4.12. DERMATOLOGICAL MEDICATION AND LOCAL THERAPEUTICS
CHRISTOS SCHAEFER AND GUDULA KIRTSCHIG
4.12.1 TOPICAL APPLICATIONS AND COSMETICS 797
4.12.2 ESSENTIAL OILS 798
4.12.3 RETINOIDS AND TOPICALS FOR PSORIASIS, DERMATITIS AND ACNE 798
4.12.4 PHOTOCHEMOTHERAPY AND FUMARIE ACID PREPARATIONS 799
4.12.5 WART REMOVAL MEDICATIONS 799
4.12.6 MEDICATIONS FOR LICE AND CABLES 799
4.12.7 EYE, NOSE AND EAR DROPS 800
4.12.8 VEIN THERAPEUTICS AND OTHER LOCAL THERAPEUTICS 801
4.12.9 VAGINAL THERAPEUTICS 801
4.13. ALTERNATIVE REMEDIES, VITAMINS, AND MINERALS
RUTH A. LAWRENCE AND ELEANOR HCITTEL
4.13.1 ALTERNATIVE REMEDIES AND PHYTOTHERAPEUTICS 803
4.13.2 HERBAL GALACTOGOGUES AND ANTIGALACTOGOGUES 805
4.13.3 TOPICAL TREATMENT FOR BREAST PROBLEMS 807
4.13.4 VITAMINS, MINERALS, AND TRACE ELEMENTS 808
4.13.5 BIPHOSPHONATES 808
4.136 EXERCISE 809
4.13.7 GLUCOSE 6-PHOSPHATE-DEHD 809
4.14. CONTRAST MEDIA, RADIONUCLIDES AND DIAGNOSTICS
STEFANIE HULTZSCH
4.14.1 *-RAY STUDIES, ULTRASOUND, AND MAGNETIC
RESONANCE IMAGING 813
4.14.2 IODINE-CONTAINING CONTRAST MEDIA 813
4.14.3 MAGNETIC RESONANCE CONTRAST AGENTS 815
4.14.4 ULTRASOND CONTRAST MEDIA 816
4.14.5 RADIONUCLIDES 816
4.14.6 DYES 817
4.14.7 OTHER DIAGNOSTICS 818
4.15. INFECTIONS DURING BREASTFEEDING
BERNKE TE WINKE, AND CHRISTOS SCHAEFER
4.15.1 COMMON INFECTIONS 822
4.15.2 CYTOMEGALY 822
4.15.3 DENGUE VIRUS 823
4.15.4 HEP^ITISA 823
4.15.5 HEPATITIS B 824
4.15.6 HEPATITISE 824
4.15.7 HEPATITIS E 824
4.15.8 HERPES SIMPLEX 825
4.15.9 HERPES ZOSTER (SHINGLES), CHICKEN POX VARICELLA) 825
4.15.10 HIV INFECTION 826
4.15.11 HUMAN T-LYMPHOTROPIC VIRUS (HTLV) 827
4.15.12 INFLUENZA 827
4.15.13 LYME DISEASE 828
4.15.14 METHICILLIN-RESISTANT
STAPHYLOCOCCUS AUREUS (MRSA) 828
4.15.15 ROTAVIRUS 828
4.15.16 TUBERCULOSIS 829
4.15.17 WESTNILEVIRUS 830
4.15.18 OTHER INFECTIOUS DISEASES 830
4.16. RECREATIONAL DRUGS
MARK ANDERSON AND MARC OPPERMANN
4.16.1 ALCOHOL 835
4.16.2 AMPHETAMINES 836
4.16.3 CAFFEINE 836
4.16.4 CANNABIS 837
4.16.5 COCAINE 837
4.16.6 NICOTINE 838
4.16.7 OPIATES, INCLUDING METHADNE 839
4.16.8 OTHER DRUG 841
4.17. PLANT TOXINS
RUTH A. LAWRENCE AND CHRISTOS SCHAEFER
4.18. INDUSTRIAL CHEMICALS AND ENVIRONMENTAL CONTAMINANTS
RUTH A. LAWRENCE AND CHRISTOS SCHAEFER
4.18.1 PERSISTENT ORGANOCHLORINE COMPOUNDS (PESTICIDES, POLYCHLORINATED
BIPHENYLS AND DIOXINS) 847
4.18.2 MERCURY 851
4.18.3 LEAD 853
4.18.4
CADMIUM 855
4.18.5
OTHER CONTAMINANTS 855
4.18.6 BREASTFEEDING DESPITE ENVIRONMENTAL CONTAMINANTS? 857
4.18.7 BREASTFEEDING AND THE WORKPLACE 858
863
|
| any_adam_object | 1 |
| author2 | Schaefer, Christof 1951- |
| author2_role | edt |
| author2_variant | c s cs |
| author_GND | (DE-588)132428474 (DE-588)132890755 |
| author_facet | Schaefer, Christof 1951- |
| building | Verbundindex |
| bvnumber | BV043721442 |
| ctrlnum | (DE-599)DNB1071573411 |
| dewey-full | 618.0461 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 618 - Gynecology, obstetrics, pediatrics, geriatrics |
| dewey-raw | 618.0461 |
| dewey-search | 618.0461 |
| dewey-sort | 3618.0461 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| edition | Third edition |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03576nam a2200817 c 4500</leader><controlfield tag="001">BV043721442</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">160817s2015 ne |||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">16,A17</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">1071573411</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780124080782</subfield><subfield code="c">Festeinband</subfield><subfield code="9">978-0-12-408078-2</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0124080782</subfield><subfield code="9">0-12-408078-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB1071573411</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="1" ind2=" "><subfield code="a">eng</subfield><subfield code="h">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">ne</subfield><subfield code="c">XA-NL</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-Er8</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">618.0461</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="130" ind1="0" ind2=" "><subfield code="a">Arzneimittel in Schwangerschaft und Stillzeit</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drugs during pregnancy and lactation</subfield><subfield code="b">treatment options and risk assessment</subfield><subfield code="c">edited by Christof Schaefer, Paul Peters, and Richard K. Miller</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">Third edition</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xxiv, 892 Seiten</subfield><subfield code="c">24 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Stillperiode</subfield><subfield code="0">(DE-588)4183337-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Stillen</subfield><subfield code="0">(DE-588)4057578-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Schwangerschaft</subfield><subfield code="0">(DE-588)4053724-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pregnancy--drug effects.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug Therapy--contraindications.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Drug-Related Side Effects and Adverse Reactions.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fetus--drug effects.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Infant, Newborn.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Lactation--drug effects.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pregnant women--Drug use.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pregnant women--Medical care.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Obstetrical pharmacology--Handbooks, manuals, etc.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fetus--Effect of drugs on--Handbooks, manuals, etc.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Newborn infants--Effect of drugs on--Handbooks, manuals, etc.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Fetus--Effect of drugs on.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Newborn infants--Effect of drugs on.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Obstetrical pharmacology.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pregnant women--Drug use.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Pregnant women--Medical care.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Handbooks, manuals, etc.</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Schwangerschaft</subfield><subfield code="0">(DE-588)4053724-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Stillen</subfield><subfield code="0">(DE-588)4057578-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Schwangerschaft</subfield><subfield code="0">(DE-588)4053724-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Stillperiode</subfield><subfield code="0">(DE-588)4183337-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2="1"><subfield code="a">Arzneimittel</subfield><subfield code="0">(DE-588)4003115-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schaefer, Christof</subfield><subfield code="d">1951-</subfield><subfield code="0">(DE-588)132428474</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Peters, P. W. J. (Paul W. J.),</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miller, Richard Kermit</subfield><subfield code="d">1946-</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)132890755</subfield><subfield code="4">oth</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">B:DE-101</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://d-nb.info/1071573411/04</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">DNB Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029133506&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029133506</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection> |
| id | DE-604.BV043721442 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:33:23Z |
| institution | BVB |
| isbn | 9780124080782 0124080782 |
| language | English German |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029133506 |
| open_access_boolean | |
| owner | DE-Er8 |
| owner_facet | DE-Er8 |
| physical | xxiv, 892 Seiten 24 cm |
| publishDate | 2015 |
| publishDateSearch | 2015 |
| publishDateSort | 2015 |
| publisher | Elsevier |
| record_format | marc |
| spelling | Arzneimittel in Schwangerschaft und Stillzeit Drugs during pregnancy and lactation treatment options and risk assessment edited by Christof Schaefer, Paul Peters, and Richard K. Miller Third edition Amsterdam ; Boston ; Heidelberg ; London ; New York ; Oxford ; Paris ; San Diego ; San Francisco ; Singapore ; Sydney ; Tokyo Elsevier 2015 xxiv, 892 Seiten 24 cm txt rdacontent n rdamedia nc rdacarrier Arzneimittel (DE-588)4003115-9 gnd rswk-swf Stillperiode (DE-588)4183337-5 gnd rswk-swf Stillen (DE-588)4057578-0 gnd rswk-swf Schwangerschaft (DE-588)4053724-9 gnd rswk-swf Arzneimittelnebenwirkung (DE-588)4003134-2 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Pregnancy--drug effects. Drug Therapy--contraindications. Drug-Related Side Effects and Adverse Reactions. Fetus--drug effects. Infant, Newborn. Lactation--drug effects. Pregnant women--Drug use. Pregnant women--Medical care. Obstetrical pharmacology--Handbooks, manuals, etc. Fetus--Effect of drugs on--Handbooks, manuals, etc. Newborn infants--Effect of drugs on--Handbooks, manuals, etc. Fetus--Effect of drugs on. Newborn infants--Effect of drugs on. Obstetrical pharmacology. Handbooks, manuals, etc. Schwangerschaft (DE-588)4053724-9 s Stillen (DE-588)4057578-0 s Pharmakotherapie (DE-588)4076066-2 s Arzneimittelnebenwirkung (DE-588)4003134-2 s DE-604 Arzneimittel (DE-588)4003115-9 s 1\p DE-604 Stillperiode (DE-588)4183337-5 s 2\p DE-604 Schaefer, Christof 1951- (DE-588)132428474 edt Peters, P. W. J. (Paul W. J.), Sonstige oth Miller, Richard Kermit 1946- Sonstige (DE-588)132890755 oth B:DE-101 application/pdf http://d-nb.info/1071573411/04 Inhaltsverzeichnis DNB Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029133506&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Drugs during pregnancy and lactation treatment options and risk assessment Arzneimittel (DE-588)4003115-9 gnd Stillperiode (DE-588)4183337-5 gnd Stillen (DE-588)4057578-0 gnd Schwangerschaft (DE-588)4053724-9 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| subject_GND | (DE-588)4003115-9 (DE-588)4183337-5 (DE-588)4057578-0 (DE-588)4053724-9 (DE-588)4003134-2 (DE-588)4076066-2 |
| title | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_alt | Arzneimittel in Schwangerschaft und Stillzeit |
| title_auth | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_exact_search | Drugs during pregnancy and lactation treatment options and risk assessment |
| title_full | Drugs during pregnancy and lactation treatment options and risk assessment edited by Christof Schaefer, Paul Peters, and Richard K. Miller |
| title_fullStr | Drugs during pregnancy and lactation treatment options and risk assessment edited by Christof Schaefer, Paul Peters, and Richard K. Miller |
| title_full_unstemmed | Drugs during pregnancy and lactation treatment options and risk assessment edited by Christof Schaefer, Paul Peters, and Richard K. Miller |
| title_short | Drugs during pregnancy and lactation |
| title_sort | drugs during pregnancy and lactation treatment options and risk assessment |
| title_sub | treatment options and risk assessment |
| topic | Arzneimittel (DE-588)4003115-9 gnd Stillperiode (DE-588)4183337-5 gnd Stillen (DE-588)4057578-0 gnd Schwangerschaft (DE-588)4053724-9 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| topic_facet | Arzneimittel Stillperiode Stillen Schwangerschaft Arzneimittelnebenwirkung Pharmakotherapie |
| url | http://d-nb.info/1071573411/04 http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=029133506&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | UT arzneimittelinschwangerschaftundstillzeit AT schaeferchristof drugsduringpregnancyandlactationtreatmentoptionsandriskassessment AT peterspwjpaulwj drugsduringpregnancyandlactationtreatmentoptionsandriskassessment AT millerrichardkermit drugsduringpregnancyandlactationtreatmentoptionsandriskassessment |
Es ist kein Print-Exemplar vorhanden.
Inhaltsverzeichnis